This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Point of View

Glyn G. Jamieson, MB, BS, FRACS; John Ludbrook, MD, ChM, FRCS, FRACS

Arch Surg. 1977;112(2):119-120.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Adjuvant chemotherapy in the treatment of cancer is suddenly fashionable. A recent editorial in the New England Journal of Medicine¹ has the title, "Major Advance in Breast Cancer Therapy," and does not follow the bold statement with a question mark. The writer of the editorial advocated that adjuvant chemotherapy should be given to all patients with early breast cancer without awaiting the outcome of further research. To give chemotherapy soon after the removal of a malignant neoplasm is an attractive approach from several aspects. It seems logical to use cytotoxic agents when residual tumor cells are minimal, and recent experience with both leukemia and Wilms tumors suggests that continuing chemotherapy against subclinical disease can be remarkably successful. As well, some experimental work with animal models has demonstrated that early chemotherapy can cure micrometastases. Undoubtedly the greatest factor in bringing adjuvant therapy into the spotlight has been the recent publication . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Surgery, University of Adelaide, Adelaide 5000, South Australia.

Footnotes
Accepted for publication Oct 13, 1976.

Reprint requests to 319 Longwood Ave, Boston, MA 02115 (Richard Warren, MD).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?